How to make your money go further

Astra vs GSK. Drugs vs Dividends.

16/11/2018 · AstraZeneca (AZN)  · GlaxoSmithKline (GSK) 

Dividends FTSE 100 Shares

Astra vs GSK. Drugs vs Dividends.
Update: AstraZeneca has failed another drugs trial. That's the risk of its strategy which has been to focus on bulking up its pipeline with exciting, novel therapies. It's very different to the 'steady as she goes' approach employed by GlaxoSmithKline which, though underwhelming, might be better for income seekers.

AstraZeneca’s (AZN) ‘Mystic’ drugs trial has failed to improve overall survival chances for lung cancer patients. Investors clearly aren’t surprised - the share price only fell 3% on the back of the announcement. Why? Because Astra’s Mystic trial has failed before. In the summer of 2017, the pharma giant suffered one of its largest ever one-day share price falls when it reported that the drugs being trialled in ‘Mystic’ had failed to halt progression free survival (which means the cancer gets no worse over a specified period of time). Then, the failure was particularly disappointing because Astra had high hopes…

Sign up and read the full article

Register to continue reading this article.

Get FREE access now

Already a member? Login

Have your say

Log in or register to view or add comments.

Get free access now

Register free to gain access to more research

Register

Investor's Champion Premium Content

Subscribers to our Premium Content receive priority notification by email of newly published research. Premium Content costs as little as £3.20 per research note.

More on Premium Content

More on AstraZeneca

Astra vs GSK. Drugs vs Dividends.

16/11/2018 · Blog
Update: AstraZeneca has failed another drugs trial. That's the risk of its strategy which has been…

More on GlaxoSmithKline

New Year, new you: profit from your resolutions

07/01/2019 · Investors Clinic
This January, thousands of us will drag ourselves into the gym, or spend our days craving…

GlaxoSmithKline split: a winning strategy?

19/12/2018 · Get Investing
Shareholders seem to like the GSK split proposal, with the price up strongly off the back…

Astra vs GSK. Drugs vs Dividends.

16/11/2018 · Blog
Update: AstraZeneca has failed another drugs trial. That's the risk of its strategy which has been…

More from the Blog

Strix Group - share based payments dwarf other costs

21/03/2019 · Strix Group PLC

Remember when the ASOS warehouse burnt down?

19/03/2019 · ASOS · Ocado

Judges Scientific: when a buy and build strategy works

19/03/2019 · Judges Scientific